During mammalian pituitary gland development, distinct cell types emerge from a common primordium. Appearance of specific cell types occurs in response to opposing signaling gradients that emanate from distinct organizing centers. These signals induce expression of interacting transcriptional regulators, including DNA binding–dependent activators and DNA binding–independent transpressors, in temporally and spatially overlapping patterns. Together they synergistically regulate precursor proliferation and induction of distinct cell types. Terminal cell type differentiation requires selective gene activation strategies and long-term active repression, mediated by cell type–specific and promoter-specific recruitment of coregulatory complexes. These mechanisms imply the potential for flexibility in the ultimate identity of differentiated cell types.

The pituitary gland is a critical component of the neuroendocrine system that is present in all vertebrates. It is essential for the maintenance of homeostasis, metabolism, reproduction, growth, and lactation. The synthesis and secretion of trophic hormones from distinct endocrine cell types in the pituitary gland is controlled by the central nervous system (via neuropeptides from the hypothalamus) and by positive and negative feedback loops from peripheral organs. The six endocrine cell types of the anterior pituitary gland elaborate proopiomelanocortin (POMC) [which is proteolytically cleaved to adrenocorticotrophic hormone (ACTH) in corticotropes and melanocyte-stimulating hormone (MSHα) in melanotropes], growth hormone (GH) in somatotropes, prolactin (Prl) in lactotropes, thyroid-stimulating hormone (TSH) in thyrotropes, and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in gonadotropes (Fig. 1). There is also an embryonic cell type referred to as the rostral tip “thyrotrope” (Fig. 1).

The pituitary gland develops in tandem with the specific hypothalamic nuclei that ultimately regulate homeostatic responses in the mature organism [reviewed in (1–3)]. Ablation and fate mapping experiments in frogs, chicks, and mice localized the pituitary anlage to the midline portion of the anterior neural ridge (ANR), immediately anterior to the cells in the neural plate that give rise to the mature primordium (reviewed in (1–3)]. Ablation and fate mapping experiments in frogs, chicks, and mice localized the pituitary anlage to the midline portion of the anterior neural ridge (ANR), immediately anterior to the cells in the neural plate that give rise to the mature organism [reviewed in (1–3)].

Extrinsic signals. The initial “extrinsic” signaling phase of murine pituitary development requires signals from both the ventral diencephalon and oral ectoderm (Fig. 2). The ventral diencephalic signals include members of the bone morphogenetic protein (BMP), fibroblast growth factor (FGF), and Wnt gene families. The onset of expression of these factors coincides with the initial development of Rathke’s pouch. Their expression differentially attenuates as specific cell lineages emerge (8–10). Another signal, Sonic Hedgehog (Shh), emanates from the oral ectoderm (8) (Fig. 2).

FGF signaling (8,9) plays an instructive role by inducing the gene encoding the LIM homeodomain transcription factor Lhx3/P-Lim, which is required for progression of pituitary development beyond the initial invagination of Rathke’s pouch (11,12). Deletion of the gene encoding FGF10 or the FGF receptor type 2 (11,12).
BMP4 is also required for continued organ development after pouch formation (Fig. 2), because targeted expression of the BMP2/4 antagonist Noggin in vivo results in the arrest of pituitary development at E10 (after invagination) and the absence of all endocrine cell types except for a few POMC-expressing cells (8). Deletion of BMP4 causes embryonic death at ~E10 and failure of invagination of Rathke’s pouch (14), although conditional gene deletion of BMP4 will be required to establish direct causality. These phenotypes indicate that ventral diencephalic FGFs and BMP4 are required for initial organ commitment, proliferation, and progression.

Shh is expressed throughout the oral ectoderm on E8 but is excluded from the invaginating Rathke’s pouch, thereby creating a clear boundary of Shh expression within the oral ectoderm. Targeted expression of the Hedgehog inhibitor HIP (Hedgehog interacting protein) in mice (15) and analysis of you-too mutants (homolog of the Shh-induced mediator Gli) in zebrafish [reviewed in (3, 15)] have shown that Shh is required for pituitary proliferation and patterning after E10—acting with FGFs to sustain ventral expression of Lhx3 (12, 13, 15)—and inducing of intrinsic BMP2 expression in the ventral pouch. This is analogous to the sequential and cooperative roles of BMPs and Hedgehog in limb and neural tube development and in organizing anterior-posterior patterning in the Drosophila wing (3, 16–18). Conversely, overexpression of Shh causes hyperproliferation of ventral gonadotropes and thyrotropes (15). Wnt factors, such as Wnt4, also regulate proliferation of anterior pituitary cell types (8).

Intrinsic signaling. Subsequent patterning of Rathke’s pouch is governed by intrinsic and ventral mesenchymal signals, including BMP2 and Wnt4 expressed in the developing gland, which establish positional identity and stimulate proliferation of specific ventral cell types. BMP2 is initially expressed in a ventral-dorsal gradient at E10.5, but by E12.5 its expression has expanded throughout the pouch (8, 9). Extrinsic signals emanating from ventral condensing mesenchyme beneath the developing pituitary gland include Indian Hedgehog (IHH), Wnt4, and BMP2. Caudal mesenchyme is a source of a Chordin signal that can oppose the function of BMP2 (8) (Fig. 2). In vivo inhibition of BMP2/4 actions causes loss of the Pit-1 lineage (see below) and gonadotropes, but not of POMC-expressing cells.

Signal attenuation. Although opposing dorsal → ventral FGF8/10/18 and ventral → dorsal BMP2 gradients appear to be associated with the positional determination of specific cell types (Fig. 2), attenuation of BMP signaling is also required for progression to terminal differentiation of pituitary cell types (8). Together, the combinatorial signal regulation of pituitary is analogous to that in many organs, including spinal cord, lung, and teeth [e.g., (17, 18)].

Combinatorial Transcriptional Regulation of Cell Type Determination

The transient signaling gradients result in the induction of expression of transcription factors in spatially overlapping patterns, as diagrammed in Fig. 2, which are proposed to be cell-autonomous determinants of pituitary cell fate. These transcription factors may be considered to act as a molecular memory of prior signals in the positional determination of specific cell types. They include classes of factors linked to development of other organs, including LIM homeodomain, paired-like homeodomain, bicoid-like homeodomain, and sine oculus–related factors (Fig. 3). Many of the initially expressed factors appear to be required to regulate expansion of the multipotent precursor cell population.

LIM homeodomain factors. Multiple members of the LIM homeodomain family of transcription factors are expressed at various stages in the developing Rathke’s pouch, including Lhx3 (P-Lim/mLim3), Lhx4 (Gsh4), Lhx2, and Is1-1 [reviewed in (1–3)]. However, there is as yet no evidence of a combinatorial LIM homeodomain factor code in pituitary development analogous to that specifying distinct spinal cord motor neuron types (19). In Lhx3 mutant mice, development ceases after the rudiment of Rathke’s pouch forms and only a few corticotropes are present, hinting that specification of this cell type is Lhx3/4-independent (11, 12). In the absence of Is1-1, which is initially expressed throughout the pouch (perhaps under BMP regulation) and then restricted to the ventral region as the ventral
to similar DNA sequences (Figs. 2 and 3). In the case of pituitary development, two related paired-like homeodomain proteins, which exert opposing functions, are both required (Fig. 3). The repressor Rpx/Hesx1 (20, 21) is expressed only in early pituitary development, before the appearance of all terminal differentiation markers except POMC (22). **Prophet of Pit-1** (**Prop-1**), which encodes a structurally related paired-like homeodomain activator, is initially detected at E10 to E10.5, with robust expression continuing until E13.5 to E14.5 (Fig. 2). Analyses of the murine Prop-1 hypomorphic mutation (22, 23) and studies of families with combined pituitary hormone deficiency involving more severe mutations in the human **PROP1** gene (24) suggest that the **Prop-1** gene (24) suggests that the **Prop-1**– dependent cell types and of gonadotropes (22, 23).

The Rpx/Hesx1 (20, 25) repressor can heterodimerize with Prop-1 and inhibit its gene activation properties (26), analogous to antagonism by Mxi1/Siamois paired-like homeodomain factors in *Xenopus* development (3). Rpx/Hesx1 appears to be important for terminal differentiation and proliferation of the pituitary gland, whereas its subsequent down-regulation appears to permit a temporal switch that leads to emergence of **Prop-1**– dependent lineages at E13.5 (22, 23, 26). Using a conserved domain (27), Rpx/Hesx1 interacts with a member of the groucho/transducin-like enhancer of split family (TLE), which exhibits similar spatial and gradient of expression, and Pax6 mutant mice exhibit an increased number of ventral thyrotrpes and gonadotropes, at the expense of the more dorsal somatotropes and lactotropes cell types (27, 28), analogous to the ventral neural tube phenotype of **Pax6** mutant mice (29). Thus, Pax6 may functionally oppose Shh signaling to specify a dorsal rather than ventral cell fate. Deletion of a genomic area that encompasses multiple transcription units including several **sine oculus** and **optix**–related genes, including **Six6**, is reported to cause human pituitary anomalies (30).

**Pitx factors.** Two bicoid-related Pitx homeodomain factors, Pitx1 and Pitx2, display distinct but overlapping patterns of expression and exert roles in the development of several organs, including pituitary [reviewed in (1–3)]. Targeted disruption of the **Pitx1** gene leads to diminished expression of terminal differentiation markers for gonadotrope and thyrotrpe cells, and increased POMC gene expression, as well as craniofacial and hindlimb morphogenesis defects (31, 32). In **Pitx2** mutant mice, the pituitary gland fails to progress beyond E10.5 and is characterized by defects in early proliferation and patterning (25, 33); these findings imply that Pitx factors may serve as cell-specific components of signaling pathways that regulate cell proliferation. Deletion of the **Pitx2** gene also results in more severe developmental defects, including block of tooth development, failure of ventral body wall closure, and right lung isomerism (25, 33, 34).

**Determination and Terminal Differentiation of Specific Cell Types**

What are the subsequent molecular mechanisms by which the six mature endocrine cell types emerge from the patterned organ? Anterior pituitary cell types are initially positionally determined as they emerge from pro-
GATA-2 binding to Pit-1, expressed at very occur in part because tropes is suggested to genes by Pit-1 in thyrogonadotrope-specific expressed (diagrammed Pit-1 and GATA-2 are in thyrotropes, both ([...](43))

Plasticity in the determination of the Pit-1-dependent activator, and both functions are consistent with assembly of a “repressosome” complex that interacts with components of the corepressor machinery in the appropriate cellular context (Fig. 5). Regulation of expression or modification of any of these factors may underlie cell type specification. Together, these data suggest a potentially flexible commitment to terminally differentiated cell types that might be prototypic of events in many organs. The human growth hormone gene, present glycoprotein subunit (αGSU), with the Pit-1– independent gonadotrope lineage. One ventrally induced factor, GATA-2 (Fig. 2), originally identified as a factor required for hematopoietic system development, has proven to be induced by the ventral → dorsal BMP2 signal (8, 43) and appears to be an important component of the gonadotrope and thyrotrope developmental programs. In gonadotropes, GATA-2 functions epistatically to other required factors, including SF1 (43) (Fig. 3). Plasticity in the determination of the Pit-1 lineages and gonadotropes is suggested by the observation that targeted expression of Pit-1 ventrally in vivo is sufficient to convert gonadotropes to thyrotropes, whereas dorsal expression of GATA-2 is sufficient to convert all of the Pit-1–dependent cell types to gonadotropes through activation of factors such as SF1 (Fig. 4).

At the highest levels of expression in the presumptive gonadotropes, GATA-2 appears to inhibit initial activation of the Pit-1 gene (43), but at lower levels in thyrotropes, both Pit-1 and GATA-2 are expressed (diagrammed in Fig. 4). Inhibition of gonadotrope-specific genes by Pit-1 in thyrotropes is suggested to occur in part because Pit-1, expressed at very high levels, can inhibit GATA-2 binding to promoters that do not contain an adjacent Pit-1 site. This effect occurs independently of Pit-1 DNA binding and reflects specific interactions between the POU domain of Pit-1 and a critical DNA binding zinc finger of GATA-2 (43). In contrast, on specific genes that contain adjacent Pit-1 and GATA-2 binding sites such as the TSHβ promoter (43, 44), Pit-1 and GATA-2 act synergistically. Thus, Pit-1 functions as a DNA binding–independent transrepressor and a DNA binding–dependent activator, and both functions are based on conserved sequences in its DNA binding domain (Fig. 4). This is likely to be a general strategy in organogenesis.

**Somatotropes and lactotropes.** Multiple Pit-1 DNA binding sites are present in the cis-acting sequences required for cell type–specific expression of the rat growth hormone and prolactin genes, and binding of Pit-1 is required for their activation (1–3). The minimal growth hormone gene information required for selective expression in somatotropes, but not lactotropes, resides in the proximal promoter, which contains evolutionarily well-conserved sequences, including two Pit-1 binding sites (3, 45). On the basis of in vivo evidence of an allosteric effect of a Pit-1 DNA site, corecystals of the Pit-1 POU domain dimer bound to growth hormone and prolactin promoter cognate sites were analyzed. The data revealed that the spacing between the DNA contacts made by the POU-specific domain (POUδ) and the POU homeodomain (POUα) of each monomer is increased by two base pairs on the growth hormone element (Fig. 5). Deletion of these two base pairs results in a failure to effectively restrict reporter gene expression from lactotropes, suggesting that a critical transcriptional activator of cell type–specific gene targets is also involved in active repression of the same gene targets in other cell types (45).

Pit-1 can associate, directly or indirectly, with either coactivators or corepressors, including N-CoR and histone deacetylases (46). Indeed, the required coactivator components have proved to be signaling pathway dependent (46), as exemplified by the Ras-dependent activation of ets/Pit-1 synergy in prolactin gene activation (47, 48). Whereas both Pit-1 and thyroid hormone receptor β (TβRβ) are present on the growth hormone gene promoter, when it is transcribed (in somatotropes) and when it is not transcribed (as in lactotropes), the corepressor N-CoR is associated only with the nontranscribed promoter and it appears to be required in vivo for cell type–specific restriction (45). Active repression of the growth hormone gene requires the actions of at least two other factors, consistent with assembly of a “repressosome” complex that interacts with components of the corepressor machinery in the appropriate cellular context (Fig. 5). Regulation of expression or modification of any of these factors may underlie cell type specification. Together, these data suggest a potentially flexible commitment to terminally differentiated cell types that might be prototypic of events in many organs.
in a cluster of five related genes, requires additional regulation by a Pit-1–dependent locus control region (LCR), located 14 to 16 kb upstream, for cell type–specific expression (49), which is itself dependent on Pit-1 binding sites.

**POMC lineages.** Cytokines such as LIF, acting via STAT3, can induce POMC gene expression and expand the POMC population, suppress Lhx3 expression, and decrease expression and expand the POMC population. Many other factors, including additional regulation by a Pit-1–dependent transcription factor, T-pit, first identified in humans (274), have been shown to be selectively expressed in POMC-producing cells and to be capable of activating the POMC gene promoter (39). Misexpression of this T-box factor in vivo, under αGSU regulatory sequences, results in expression of ACTH in normally nonexpressing rostral tip cells (39) and a decrease in αGSU and TSHβ expression (51). In human kindreds, defective ACTH production is clearly correlated with mutations of the human Tbx19/T-pit gene (39), indicating that T-pit is an important component of the corticotrope developmental program. Many other factors, including Pitx1/Pitx2, Nur77, and Neuro D1 (39, 50, 52–54), regulate POMC gene expression in model cell lines, but their exact biological roles in POMC gene expression remain to be determined.

**Conclusions**

The development of specific cell types in the pituitary is directed by transient signaling gradients that induce nuclear mediators of cell type commitment, including transcription factors acting as repressors or activators, and their associated coregulators. These factors integrate, at the level of gene expression, the output in response to multiple signaling pathways. A more comprehensive understanding of the molecular strategies that underlie cell determination and proliferation in the pituitary can be expected with the availability of ever more powerful cell biological, genomic, and genetic screening approaches.

**References and Notes**

27. C. A. Bentley et al., Endocrine 10, 171 (1999).
55. We apologize to our colleagues whose important contributions we could not cite because of space limitations. We thank R. Burgess, A. Gleiberman, O. Hermanson, and L. Olson for helpful discussions; M. Treier and J. Dasen for their important contributions; and P. Myer and M. Fisher for assistance in figure and manuscript preparation. M.G.R. is an HHMI Investigator. Supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases.

www.sciencemag.org SCIENCE VOL 295 22 MARCH 2002

G000AAAAALLLL! AAAS members get the clearest shot on the Net.

With fully searchable archives back to 1880 through JSTOR, and pre-print access to breakthrough research online with Science Express, you can’t lose with your personal AAAS membership. In addition to your subscription to Science, we have an unbeatable team of member benefits to keep you in the lead in the lab, in the library or at home. You’ll be equipped with a daily news service, career advice, book discounts, email alerts and much more to give you the home field advantage every time. AAAS and Science, an unbeatable team!

promo.aas.org/getsience